A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With Entecavir

Inclusion Criteria: * Has given voluntary written informed consent before performance of any study related procedure. * Are treatment naive or without HBV treatment for at least 60 days or 5 times the elimination half-life, whichever is longer. * Patient has CHB: 1. HBV DNA ≥ 20,000 IU/mL for HBeAg positive and ≥2'000 for HBeAg negative and 2. HBsAg ≥ 2.5 log10 IU/mL. * Has liver imaging to screen for hepatocellular carcinoma or concomitant pancreaticobiliary disease either in the prior 6 months or at screening. * Patient is not of childbearing potential or, if of childbearing potential, is not pregnant as confirmed by a negative serum human chorionic gonadotropin test at screening and is not planning a pregnancy during the course of the study. Exclusion Criteria: * Is an employee of a clinical research organization, vendor, or Sponsor involved with this study. * Has known hepatocellular carcinoma or pancreaticobiliary disease. * Neutropenia (defined by two confirmed values during Screening period of \< 1500/μL). * Has Gilbert syndrome. * Shows evidence of worsening liver tests, defined as either a confirmed (2 assessments at least 3 days apart) increase \> 2 ULN ALT or AST or an increase of \> 1.5 × baseline value of TBL or associated with clinical signs or symptoms of liver impairment. * Has known or suspected non-CHB liver disease * History of cirrhosis or liver decompensation, including ascites, hepatic encephalopathy, or presence of oesophageal varices. * Probable or possible F4 stage with a vibration controlled transient elastography (VCTE) \> 11.7 kPa leads to exclusion * Has known history of alcohol abuse or daily heavy alcohol consumption * Has any of the following exclusionary laboratory results at screening: 1. ALT \> 2 × ULN, AST \> 2 × ULN 2. INR \> 1.2 × ULN, (normal range is 0.8 to 1.2) 3. Platelet count \< 100 G/L 4. Estimated glomerular filtration rate \< 50 mL/min/1.73m2 (the Modification of Diet in Renal Disease formula) 5. Thyroid-stimulating hormone \> 1.5 × ULN or abnormal free triiodothyronine or free thyroxine.